JCAR 023

Drug Profile

JCAR 023

Alternative Names: Anti-CD171-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-chimeric-antigen-receptor-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-product-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; Anti-L1CAM-CAR-T-cell-therapy-Juno-Therapeutics; Anti-neural-cell-adhesion-molecule-L1-chimeric-antigen-receptor-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-product-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; JCAR023

Latest Information Update: 01 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Childrens Research Institute
  • Developer Juno Therapeutics
  • Class Cancer vaccines; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; Neural cell adhesion molecule L1 inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuroblastoma

Most Recent Events

  • 19 Mar 2015 Phase-I clinical trials in Neuroblastoma (In infants, In children, In adolescents, Recurrent, Refractory metastatic disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top